CORRONA Presentations at ACR 2016 Save

Jack Cush, MD

Nov 13, 2016 7:49 pm

CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.

*Poster Title*	*Authors*	*Presentation #*	*Location*
Sunday, November 13, 9-11am
Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease among patients with RA	John AK, Prehn AW, Tawfik H, Reed GW, Kremer JM	22	Poster Hall C -Row 1
Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis	John AK, Prehn AW, Tawfik H, Reed GW, Kremer JM	23	Poster Hall C -Row 1
Modifiable rheumatoid arthritis factors and impact on cardiovascular risk	Katherine P. Liao, Carol J. Etzel, Jeff Greenberg, Hongshu Guan, Joel M. Kremer, Daniel H. Solomon	24	Poster Hall C -Row 1
Work Status in Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: Findings from a US Observational Cohort	Alemao E, Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S Kremer JM	549	Poster Hall C -Row 5
Higher Multi Biomarker Disease Activity Scores Foreshadow Greater Longitudinal Improvement in RA Disease Activity	Curtis JR, Harrold L, Kremer J, Palmer L.	556	Poster Hall C -Row 5
Disease Activity Trends after Dose Escalation of Infliximab (Remicade)– Results from United States Corrona Registry	Parenti D, Reed GW, Shan Y, Dandreo KJ, Kremer JM, DeHoratius R	600	Poster Hall C -Row 6
Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs	Boytsov N, Reed GW, Harrold LR, Xiang Z, Gaich CL, Larmore CJ, Shan Y, Rebello S Araujo AB	637	Poster Hall C -Row 6
Monday, November 14, 9-11am
Impact of Rituximab on PatientReported Outcomes in Patients with Rheumatoid Arthritis from the US Corrona Registry	Harrold LR, John A, Best J, Zlotnick S, Karki C, Li Y, Greenberg JD, Kremer JM	1580	Poster Hall C -Row 5
Comparative Effectiveness of Tocilizumab Monotherapy With Tumor Necrosis Factor Inhibitors in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors	Harrold LR, Reed GW, Best J, Zlotnick S, Persuitte G, Kremer JM	1596	Poster Hall C -Row 5
Clinical Responses to Tocilizumab Analyzed by Serologic status in Rheumatoid Arthritis	Cappelli L, Palmer JL, Bingham CJ	1603	Poster Hall C -Row 5
Predictors of Persistency with TNFi in Biologic Experienced Versus Biologic Naive Psa Patients Enrolled in the Corrona Registry	Etzel CJ, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Harrold LR	1679	Poster Hall C -Row 6
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis—Descriptive Analysis From the Corrona PsA/SpA Registry	Mease PJ, Karki C, Liu M, Kavanaugh A, Pandurengan R, Ritchlin CT, Palmer JB, Greenberg JD,	1683	Poster Hall C -Row 6
Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona PsA/SpA Registry	Mease PJ, Karki C, Liu M, Kavanaugh A, Ritchlin CT, Huynh D, Pandurengan R, Palmer JB, Greenberg JD,	1702	Poster Hall C -Row 6
Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors	Ogdie A, Palmer L, Greenberg J, Curtis J, Harrold L, Solomon D, Kavanaugh A, Kremer J, Mease P.	1722	Poster Hall C -Row 6
Tuesday, November 15, 9-11am
Impact of Poor Prognosis Factors on Treatment Decisions in Clinical Practice in Patients with Rheumatoid Artritis: Findings from a US Observational Cohort	Harrold LR, Alemao E, Litman HJ, Connolly SE, Kelly S, Hua W, Rosenblatt L, Rebello S Kremer JM	2478	Poster Hall C -Row 4
The Real-World Comparative Safety of Certolizumab Pegol as Compared to Other TNFi in a National US Rheumatoid Arthritis Cohort	Harrold LR, Litman HJ,2 Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Yassine M	2588	Poster Hall C -Row 5
Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry.	Kavanaugh A, Geier J, Bingham C, Chen C, Reed GW, Saunders KC, Chen Y, Koenig A, Cappelli L, Greenberg JD, Kremer JM	2595	Poster Hall C -Row 5
Time to initiation of biologic agents is associated with Glucocorticoid use: Results from the Corrona registry	Pappas DA, Griffith J, Litman HJ, Schlacher CA, Salim BA, Karki C, Kremer JM	2597	Poster Hall C -Row 5
Therapy with Biologic Agents after Diagnosis of Solid Malignancies; Results from the Corrona Registry	Pappas DA, Rebello S, Liu M, Schenfeld J, Li Y, Collier DH, Accortt N,	2605	Poster Hall C -Row 5
Impact of Nail Psoriasis on Clinical Presentation of Psoriatic Arthritis—Descriptive Analysis From the Corrona PsA/SpA Registry	Mease PJ, Palmer JB, Litman HJ, Karki C, Greenberg JD	2721	Poster Hall C -Row 6
Discontinuation of Biologic Therapy in Patients With Ankylosing Spondylitis—Data From the Corrona PsA/SpA Registry	Mease PJ, van der Heijde D, Karki C, Liu M, Pandurengan R, Park Y,Greenberg JD,	2728	Poster Hall C -Row 6